Krystal Biotech reports gene therapy delivers CFTR protein to CF patients
Tweet Send to a Friend
Krystal Biotech Inc. (NASDAQ: KRYS) reported positive interim results from its Phase 1 CORAL-1 study showing that its gene therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
